

CURRICULUM VITAE of MARIE-CHRISTINE BISSERY

Dec 2004

Citizenship: French

Professional address: AVENTIS PHARMA, S.A.,
13, quai Jules Guesde, 94403 Vitry sur Seine, France.
tel. 33 1 58 93 80 18, fax. 33 1 58 93 34 71,
e-mail : marie-christine.bissery@aventis.com

CAREER OVERVIEW

- Broad oncology experience, 16 years in industry, 7 years in academia, including 5 years in Phase I clinical unit.
- Built strong and efficient networks with academic research centers, hospitals, and regulatory authorities.
- Major achievements: key contribution to the discovery and development of Taxotere and CPT-11, both being marketed; development of several other agents presently in clinical trials, two new taxoids XRP9881A and XRP6258, an antisense- Genasense, an antivascular agent AVE8062A, and an antiangiogenic VEGF-Trap.
- Determinant support to global project teams for all the above projects.
- Presently leading a group of 35 scientists, and broadening scope of competence by incorporating new technologies (genomic, proteomic, imaging) to further enable translational research for development of targeted therapies in anti-angiogenesis, signal transduction inhibition, and monoclonal antibodies.
- Author of 57 papers, 12 book chapters, 155 abstracts and 14 patents.

PROFESSIONAL EXPERIENCE

1-RESEARCH

- 2004 **AVENTIS PHARMA, S.A.**, Oncology Disease Group, VITRY SUR SEINE, France
Senior Distinguished Scientist/Senior Director, Experimental Therapeutics
Team of 35 including 7 PhD's.
See below for scope of activities
- 2003 **AVENTIS PHARMA, S.A.**, Oncology Disease Group, VITRY SUR SEINE, France
Director Experimental Therapeutics – Team of 27 including 5 PhD's.
Member of the Oncology Management Team
Member of the In Licensing Team
Member of the Joint Development Committee of Immunogen Alliance
Project Team Member: AVE8062A, 3 Immunogen mAbs, (Taxotere, CPT-11, ad hoc member)
Evaluation of in licensing opportunities including due diligence
- 2000- 2002 **AVENTIS PHARMA, S.A.**, Oncology Disease Group, VITRY SUR SEINE, France
Director Pathology and Animal Models – Team of 15 including 2 PhD's.
Project Team Member: Taxotere, XRP9881, XRP6258, Flavopiridol, ALVAC-CEAB7;
Project Team Leader : AVE8062A
Coordination and supervision of external preclinical studies for Taxotere, AVE8062,
Evaluation of in licensing opportunities including due diligence
- 1988- 1999 **RHÔNE-POULENC RORER, S.A.**, Oncology Disease Group, VITRY SUR SEINE, FRANCE
1995-1999 Reseach Advisor /Director, 14-16 technicians, 2 PhD's, 1 sr scientist -
1988-1994 Head Experimental Therapeutics, 14 technicians, 1 PhD, 1 sr scientist -
Established an in vivo and an in vitro solid tumor laboratory

Project Team Member: Taxotere, CPT-11, Giroline, Intoplicine, XRP9881, XRP6258

Developed both Taxotere (lead stage) and CPT-11 (in licensing pre-EDC stage) through launch, including clinical development, regulatory filings, and marketing activities

Coordination and supervision of external preclinical studies for Taxotere (US, EU, Jpn), and CPT-11 in the EU.

Evaluation of in licensing opportunities including due diligence

- 1984-1988 **WAYNE STATE UNIVERSITY**, School of Medicine, Hematology/Oncology Department, DETROIT, MI, USA. Drug Discovery and Evaluation Laboratories (Dr Corbett).
Field of research: Discovery of new antitumor agents; cancer chemotherapy in murine and human tumors; pharmacology of new agents; tumor model characterization.
Contract work for NCI, Eli Lilly, Upjohn and Warner Lambert Laboratories, and academic labs.
Clinical experience – joint MD/PhD program.
- 1982-1984 **MICHIGAN CANCER FOUNDATION**, School of Medicine, Hematology/Oncology Department, DETROIT, MI, USA. Experimental therapeutics (Dr Valeriote).
Field of research: Evaluation of anticancer agent- loaded microspheres in murine tumors.
In vivo models, CFUGM, DNA alkaline elution, Flow cytometry, PK determination, radiolabelled distribution studies, MRI of tumor bearing mice.
Clinical experience – joint MD/PhD program.
- 1981-1982 **WASHINGTON UNIVERSITY**, St. LOUIS, MO, USA.
Biological Transport Laboratory (Dr Thies) and Mallinkrodt Institute of Radiology, Washington University, School of Medicine (Dr Valeriote).
Field of research: Design and characterization of microspheres for chemoembolisation and targeted therapy.
Polymer sciences, Physical determination (Tg, Xray diffraction, HPLC, Head space analysis, Differential calorimetry), Drug release characteristics.

2-ACADEMIC APPOINTMENTS AND TEACHING EXPERIENCE

- 1988 - on **Invited Faculty** at international courses: Joint American Association for Cancer Research, and American Association for Clinical oncology workshops, NCI EORTC workshops, European School of Oncology, European School of Hematology, Diplome d'études Approfondies.
- 1987-1988 **Assistant Professor**, School of Medicine, Wayne State University, Michigan, U.S.A.
Supervision of MD's and PhD's training in Experimental Therapeutics
- 1986-1987 **Instructor**, School of Medicine, Wayne State University.
Supervision of MD's and PhD's training in Experimental Therapeutics
- 1982-1986 **Research Associate**, Michigan Cancer Foundation and Wayne State University.
Supervision of MD's and PhD's training in Experimental Therapeutics
- 1981-1982 **Research Associate**, Washington University, School of Engineering, St Louis, MO,U.S.A., and Université de Paris Sud XI, Centre Pharmaceutique, Châtenay-Malabry, France.
Taught 3 Microencapsulation Short Courses.

EDUCATION

- 1984-1986 **Post-Doctorate**, Department of Experimental Therapeutics, Michigan Cancer Foundation, and Oncology Department, Wayne State School of Medicine, Detroit, Michigan, U.S.A.
- 1981-1984 **Ph.D. in Pharmaceutical Sciences** (Doctorat d'Etat Es Sciences Pharmaceutiques), Université de Paris XI, France. Research done at Washington University and Michigan Cancer Foundation

- 1983 **M.Sc. in Industrial Pharmacy** (Diplôme d'Etudes Approfondies de Pharmacie Industrielle et de Biopharmacie), Université de Paris XI.
- 1981 **Doctorate in Pharmacy** (Doctorat d'Exercice en Pharmacie), Université de Paris XI- Option Recherche et Industrie.

CONTINUING EDUCATION

Major courses attended: Oncology short course ; Post graduate Course in Medical Oncology ; Curative Therapies and management of Toxicities ; Biology and Therapy of Acute Leukemia ; Biochemical modulation of Anticancer Agents- experimental and clinical approaches ; Critical issues in Tumor microcirculation angiogenesis and metastasis ; Mechanism of Cancer metastasis ; Electron Microscopy in Tumor Diagnosis ; and courses related to accreditation to direct and perform animal related studies.

AWARDS

- 1994 Rhône-Poulenc, Research Award.
- 1986 French National Academy of Pharmaceutical Sciences Award.
- 1985 Association de Pharmacie Galénique Industrielle Award.

GRANTS AND FELLOWSHIPS

- 1985-1988 National Institute of Health - RO1CA43886, Chemotherapy, Drug discovery, Pancreatic Tumors of Mice (co-investigator); RO1CA42449, Antitumor Effects of Flavone Acetic Acid (co-investigator); RFA, Drug Discovery-Anticancer Agents for Colorectal Cancer (co- principal investigator).
- 1982-1984 Fondation pour la recherche médicale, Paris.
- 1982 Philippe Foundation, New York.
- 1981 Merck Sharp and Dohme Laboratories, Paris.
- 1981 Fondation Paul Neumann pour le développement de La Recherche, Paris.

PROFESSIONAL SOCIETIES

American Association for Cancer Research (AACR), USA.

American Association of Clinical Oncology (ASCO), USA.

Pharmacokinetics, Metabolism and Mechanisms Group (PAMM) of the European Organisation for Research and Treatment of Cancer (EORTC).

Controlled Release Society, U.S.A.

Société Française du Cancer, France.

Société Française d'Expérimentation Animale, France.

CONSULTATIVE COMMITTEES

- 2002- on AACR: Awards and Program Committees
- 1985 Consultant for Lim Technology Laboratories Inc. (Richmond, VA).
- 1983-1984 Consultant for the Controlled Release Society on the scopes of the society committee (USA).

SCIENTIFIC JOURNALS EDITION

Reviewer for the following journals: Cancer Research, British Journal of Cancer, Investigational New Drugs, Annals of Oncology, European Journal of Cancer.

PUBLICATIONS

- a) patents (14)
- b) papers (57), book chapters (12), theses (3)
- c) abstracts: 155
- d) presentations: over 100 not included

PUBLICATIONS

a) Patents

1. Antitumor compositions containing Taxane derivatives (US 5,728,687)
2. Antitumor compositions containing Taxane derivatives (US 5,908,835)
3. Method for treating abnormal cell proliferation in the brain (US 6,156,789)
4. Antitumor compositions containing Taxane derivatives (US 6,214,863)
5. Antitumor compositions containing Taxane derivatives (US 6,239,167)
6. Use of a taxoid to treat abnormal cell proliferation in the brain (US 6,346,543)
7. Use of taxoid derivatives (US 6,403,634)
8. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer (US6,545,010)
9. Composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer (US6,548,488)
10. Composition comprising camptothecin or a camptothecin derivative and a stilbene derivative for the treatment of cancer (US6,562,834)
11. Antitumor compositions containing Taxane derivatives (US 6,441,026)
12. Composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer (US6,503,889)
13. Compositions antitumorales contenant des dérivés des Taxanes granted in 23 countries (W094/10995).
14. Nanoparticules stabilisées et filtrables dans des conditions stériles (WO95/35101)

b) Papers

1. Corbett, T.H., Bissery, M.C., Wozniak, A., Plowman, J., Polin, L., Tapazoglou, E., Dieckman, J. and Valeriote, F. Activity of Flavone Acetic Acid (NSC 347512) Against Solid Tumors of Mice. *Investigational New Drugs* 4:207-220, 1986.
2. Bissery, M.C., Valeriote, F.A., Chabot, G.G., Crissman, J.D. and Corbett, T.H. Flavone Acetic Acid (NSC 347512)-Induced DNA damage in Glasgow Osteogenic Sarcoma In Vivo. *Cancer Research* 48 (5):1279-1285, 1988.
3. Evelhoch, J.L., Bissery, M.C., Chabot, G.G., Simpson, N.E., Mc Coy C.L., Heilbrun, L.K. and Corbett, T.H. Flavone Acetic Acid (NSC-347512)-Induced Modulation of Murine Tumor Physiology Monitored by In Vivo Nuclear Magnetic Resonance Spectroscopy. *Cancer Research* 48 (17): 4749-4755, 1988.
4. Chabot, G.G., Bissery, M.C., Rutkowski, K., Corbett, T.H., Valeriote, F.A. and Baker, L.H. Pharmacodynamics and Causes of Dose-Dependent Pharmacokinetics of Flavone Acetic Acid (LM-975; NSC-347512). *Cancer Chemotherapy and Pharmacology*, 24: 15-22, 1989.
5. Corbett, T.H., Bissery, M.C., Mucci-LoRusso, P., and Polin, L. 5-Fluorouracil containing combinations in murine tumor systems. *Investigational New Drugs*, 7:37-49, 1989.
6. Mucci-LoRusso, P.L., Polin, L., Bissery, Valeriote, F.A., Plowman, J. and Corbett, T.H. Activity of Batracylin (NSC320846) against solid tumors of mice, *Investigational New Drugs*, 7:295-306, 1989.
7. Chabot, G.G., Bissery, M.C. and Gouyette, A. Flavone Acetic Acid (LM975, NSC-347512) Activation to Cytotoxic Species In Vivo and In Vitro. *Cancer Chemotherapy and Pharmacology*, 24:273-276, 1989.
8. De Neve, W., Evelhoch, J., Everett, C., Simpson, N., Bissery, M.C., Corbett, T.H. and Valeriote. Interaction Between Flavone Acetic Acid (LM-975, NSC 349512) and Radiation in Glasgow's Osteogenic Sarcoma In Vivo. *Int. J. Radiation Oncology Biol. Phys.*, 18 (6):1359-1365, 1990.

9. Nguyen Chi Hung, Lhoste, J.M., Lavelle, F., Bissery, M.C. and Bisagni, E. Synthesis and Antitumor Activity of 1-(Dialkylamino) alkylamino-4-Methyl-5H-pyrido (4,3-b) benzo (e) and benzo (g) indoles. A new class of Antineoplastic Agents. *J. Med. Chem.*, 33:1519-1528, 1990.
10. Giorgi-Renault, S., Renault, J., Gebel-Servolles, P., Baron, M., Paoletti, C., Cros, S., Bissery, M.C., Lavelle, F. and Atassi, G. Heterocyclic Quinones XVI. A new In Vivo Active Antineoplastic Drug: 6,7-Bis (1-aziridiny)-4 (3-(N,N- dimethylamino) propyl-amino)-5,8-quinazolinedione. *J. Med. Chem.*, 34:38-46, 1991.
11. Bissery, M.C. and Chabot G.G. Historique et récents développements des méthodes de criblage et d'évaluation des molécules anticancéreuses in vitro et in vivo. *Bulletin du Cancer*, 78:587-602, 1991.
12. Bissery, M.C., Guénard, D., Gueritte-Voegelein, F. and Lavelle, F. Experimental Antitumor Activity of Taxotere® (RP56976, NSC 628503), a Taxol Analog, *Cancer Research*, 51:4845-4852, 1991.
13. Nguyen C. H., Bisagni, E., Lavelle, F., Bissery, M.C. and Huel, C. Synthesis and antitumor properties of new 4-methyl-substituted-pyrido (4,3-b)indoles (gamma-carbolines). *Anticancer Drug Design*, 7:219-233, 1992.
14. Nguyen C. H., Lavelle, F., Riou, J.F., Bissery, M.C., Huel, C. and Bisagni, E. Further SAR in the new antitumor 1-amino-substituted gamma-carbolines and 5H-benzo(e)pyrido(4,3-b)indoles series. *Anti-Cancer Drug Design*, 7:235-251, 1992.
15. Hanauske, A.R., Degen, D., Hilsenbeck, S.G., Bissery, M.C., and Von Hoff, D.D. Effects of Taxotere® and taxol on in vitro colony formation of freshly explanted human tumor cells. *Anti-Cancer Drugs*, 3 : 121-124, 1992.
16. André, S., Bissery, M.C., Riou, J.F., Bayssas, M., Le Bail, N., and Lavelle, F. Taxotere® (RP 56976, NSC 628503) : current status of development. *Cellular Pharmacology*, 1993, 1 (suppl. 1), 567-571.
17. Boven, E., Venema-Gaberscek, E., Erkelens, C.A.M., Bissery, M.C., and Pinedo, H.M. Antitumor activity of Taxotere® (RP 56976, NSC 628503) a new taxol analog, in experimental ovarian cancer. *Annals of Oncology*, 4: 321-324, 1993.
18. Eckardt, J.R. Burris, H.A., Kuhn, J.G., Bissery, M.C., Klink-Alakl, M., Clark, G.M., Von Hoff, D.D. Activity of Intoplicine (RP 60475), a new topoisomerase I and II inhibitor, against human tumor colony forming units in vitro. *Journal of the National Cancer Institute*, 86 (1): 30-33, 1994.
19. Houghton, P.J., Cheshire, P.J., Hallman, J.C., Bissery, M.C., Mathieu-Boué, A., and Houghton, J.A. Therapeutic efficacy of the topoisomerase I inhibitor CPT-11 against human tumor xenografts: Lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor topotecan. *Cancer Research*, 53 (12): 2823-2829, 1993.
20. Maurer, H.R., Eckert, K., and Bissery, M.C. Taxotere® inhibits proliferation and induces the differentiation of HL-60 and K562 human myeloid leukemia cells in vitro. *International Journal of Oncology*, 3 : 161-165, 1993.
21. Bissery, M.C., Nguyen, C.H., Bisagni, E., Vrignaud, P., and Lavelle, F. Antitumor activity of intoplicine (RP 60475, NSC 645008), a new benzo-pyrido-indole: evaluation against solid tumors and leukemias in mice. *Investigational New Drugs*, 11 (4): 263-277, 1993.
22. Riou, J.F., Fossé, P., Nguyen, C.H., Larsen, A.K., Bissery, M.C., Grondard, L., Saucier, J.M., Bisagni, E., and Lavelle, F. RP 60475 and derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities. *Cancer Res.*, 53 (24): 5987-5993, 1993.
23. Vogel, M., Hilsenbeck, Depenbrock, H., Danhauser-Riedl, S., Block, T., Nekarda, H., Fellbaum, Ch., Aapro, M.S., Bissery, M.C., Rastetter, J. And Hanauske, A.R. Preclinical activity of Taxotere® (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells : comparison with Taxol and conventional antineoplastic agents. *Eur. J. Cancer* 29 (14): 2009-2014, 1993.

24. Massaad, L., Chabot, G., G., Toussaint, C., Koscielny, S., Morizet, J., Bissery, M.C., Gouyette, A. Influence of tumor size on main drug metabolizing enzyme systems in mouse colon adenocarcinoma Co 38. *Cancer Chemotherapy and Pharmacology*, 34 (6): 497-502, 1994.
25. Ojima, I., Duclos, O., Zucco, M., Bissery, M.C., Combeau, C., Vrignaud, P., Riou, J.F., Lavelle, F. Syntheses and structure-activity relationships of the new antitumor taxoids. Effects of cyclohexyl substitution at the C-3' and/or C-2 of Taxotere® (docetaxel). *J Med Chem*, 37 (16): 2602-2608, 1994.
26. Ribrag, V., Massaad, L., Janot, F., Morizet, J., Bissery, M.C., Parise, O., Gouyette, A., and Chabot, G.G. Main drug-metabolizing enzyme systems in L1210 leukemia sensitive or resistant to BCNU in vivo. *Leukemia Research* 18:(11): 829-835, 1994.
27. Mailliet, P., Segal-Bendirdjian, E., Kozelka, J., Barreau, M., Baudoin, B., Gontier, S., Bissery, M.C., Laoui, A., Lavelle, F., Le Pecq, J.B., Chottard, J.C. Asymmetrically substituted ethylenediamine platinum (II) complexes as antitumor agents : synthesis, structure activity relationships. *Anticancer Drug Design* 10 (1): 51-73, 1995.
28. Bissery, M.C., Nohynek, G., Sanderink, G., and Lavelle, F. Docetaxel (Taxotere®): a review of preclinical and clinical experience. Part I: Preclinical experience. *Anticancer Drugs*, 6 (3): 339-55, 363-8, 1995.
29. Dykes, D.J., Bissery, M.C., Harrison, S.D., and Waud, W.R. Response of human tumor xenografts in athymic nude mice to Taxotere®. *Investigational New Drugs*, 13 (1): 1-11, 1995.
30. Lavelle, F., Bissery, M.C., Combeau, C., Riou, J.F., Vrignaud, P., André, S. Preclinical evaluation of docetaxel (Taxotere®). *Seminars in Oncology*, 22 (2 Suppl 4): 3-16, 1995.
31. Nguyen, C.H., Fan, E., Riou, J.F., Bissery, M.C., Vrignaud, P., Lavelle, F., Bisagni, E. Synthesis and biological evaluation of amino-substituted benzo[*f*]pyrido[4,3-*b*]quinoxalines: A new class of antineoplastic agents. *Anticancer Drug Design*, 10 (4): 277-297, 1995.
32. Bissery, M.C. Preclinical activity of docetaxel (Taxotere®). *European Journal of Cancer*, 31A, suppl. 4, S1-S6, 1995.
33. Corbett et al. Tumor models and the discovery and secondary evaluation of solid tumor active agents. *International Journal of Pharmacognosy*, vol. 33, suppl. pp 102-122, 1995.
34. Bissery, M.C., Vrignaud, P., Lavelle, F. Preclinical profile of docetaxel (Taxotere®): efficacy as a single agent and in combination. *Seminars in Oncology*, 22 (6 Suppl 13): 3-16, 1995.
35. Lavelle, F., Bissery, M.C., André, S., Roquet, F., and Riou, J.F. Preclinical evaluation of CPT-11 and its active metabolite SN-38. *Seminars in Oncology*, 23 (1 Suppl 3): 11 -20, 1996.
36. Fromes, Y., Gounon, P., Veitia, R., Bissery, M.C., and Fellous, A. Influence of microtubule-associated proteins on the differential effects of paclitaxel and docetaxel. *Journal of Protein Chemistry*, 15 (4): 377-88, 1996.
37. Abigeres, D., Armand, J.P., Chabot, G.G., Catimel, G., Bruno, R., Bissery, M.C., Bayssas, M., Klink Alaki, M., and Clavel, M. Phase 1 and pharmacology study of Intoplicine (RP 60475; NSC 645008), a novel topoisomerase I and II inhibitor, in cancer patients. *Anti Cancer Drugs*, 7 (2): 166-174, 1996.
38. Bissery, M.C., Vrignaud, P., Lavelle, F., Chabot, G.G. Experimental antitumor activity and pharmacokinetics of the camptothecin analogue irinotecan (CPT-11) in mice. *Anti Cancer Drugs*, 7 (4): 437-460, 1996.
39. Vassal, G., Terrier-Lacombe, M.J., Bissery, M.C., Vénuat, A.M., Gyergyay, F., Bénard, J., Morizet, J., Boland, I., Ardouin, P., Bressac-de-Paillerets, B., Gouyette, A. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumor and neuroblastoma xenografts. *British Journal of Cancer*, 74 (4): 537-545, 1996.
40. Bissery, M.C., Vrignaud, P., Lavelle, F., Chabot, G.G. Preclinical antitumor activity pharmacokinetics of Irinotecan (CPT-11) in tumor bearing mice. In: *The Camptothecins*

discovery to the Patients. P Pantazis, B.C. Giovanella and M. C. Rothenberg, editors. Annals of the New York Academy of Sciences, 803: 173-180, 1996.

41. Ojima, I., Slater, J.C., Michaud, E., Kuduk, S.D., Bounaud, P.Y., Vrignaud, P., Bissery, M.C., Veith, J.M., Pera, P., Bernacki, R.J. Syntheses and structure-activity relationships of the second generation antitumor taxoids. Exceptional activity against drug-resistant cancer cells. *J. Med. Chem.*, 39 (20): 3889-3896, 1996.
42. Lorusso, P., Demchik, L., Foster, B., Knight, J., Bissery, M.C., Polin, L., Leopold, W.R., Corbett, T.H. Preclinical antitumor activity of CI-994 (Acetyldinaline; PD123654). *Investigational New Drugs*, 14: 349-356, 1996.
43. Vassal, G., Boland, I., Santos, A., Bissery, M.C., Terrier-Lacombe, M.J., Morizet, J., Sainte-Rose, C., Lellouch-Tubiana, A., Kalifa, C., and Gouyette, A. Potent therapeutic activity of Irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice. *Int. J. Cancer* 73 (1): 156-163, 1997.
44. Veitia, R., Bissery, M.C., Martinez, C., and Fellous, A. Tau expression in model adenocarcinomas correlates with docetaxel sensitivity in tumor bearing mice. *British Journal of Cancer*, 78 (7): 871-877, 1998.
45. Tampellini, M., Filipski, E., Liu, X.H., Lemaigre, G., Li, X.M., Vrignaud, P., François, E., Bissery, M.C. and Lévi, F. Docetaxel chronopharmacology in mice. *Cancer Res.*, 58 (17): 3896-3904, 1998.
46. Veitia, R., Ottolenghi, C., Bissery, M.C., and Fellous, A.. A novel human gene encoding a potential protein conserved from yeast to man, is strongly expressed in testis and cancer cell lines. *Cytogenetics and cell genetics* 85 (3-4): 217-220, 1999.
47. Vrignaud P., Bissery M.-C., Mailliet P., Lavelle F. RPR 130401, a non-peptidomimetic farnesyl transferase inhibitor with in vivo activity, in *Anticancer Molecules, Structure, function and Design*, edited by Hiroshi Maruta, Annals of the New York Academy of Sciences, Vol 886, pp249-251, 1999.
48. Veitia, R., David, S., Barbier, P., Vantard, M., Gounon, P., Bissery, M.C., and Fellous, A. Proteolysis of microtubule associated protein 2 and sensitivity of pancreatic tumors to docetaxel, *British Journal of Cancer*, 83 (4): 544-549, 2000.
49. Granda T.G., Filipski E., D'Attino R.M., Vrignaud P., Anjo A., Bissery M.C., and Lévi F. Experimental chronotherapy of mouse mammary adenocarcinoma MA13/C with docetaxel and doxorubicin as single agents and in combination. *Cancer Res.*, 61(5):1996-2001.
50. Bissery, MC, Preclinical evaluation of new taxoids, *Current Pharmaceutical Design*, 7, 1251-1257, 2001.
51. Campone, M., Fumoleau, P., Delecroix, V., Deporte-Fety, R., Perrocheau, G., Vernillet, L., Borg-Olivier, O., Louboutin, J.P., Bissery, M.C., Riva, A., and Azli, Phase I dose finding and pharmacokinetic study of docetaxel and vinorelbine as first line chemotherapy for metastatic breast cancer. *Ann Oncol* Jul 12 (7), 909-918, 2001.
52. Granda T.G., D'Attino R.M., Filipski E., Vrignaud P., Garufi C., Terzoli E., Bissery M.C., and Lévi F. Circadian optimization of irinotecan and oxaliplatin in mice with Glasgow osteosarcoma. *British Journal of Cancer*, 86, 999-1005, 2002.
53. Bernard-Marty, C, Treilleux, I, Dumontet, C, Cardoso, F, Fellous A., Gancberg, D, Bissery, MC, Paesmans, M., Larsimont, D., Piccart MJ, Di Leo, A. Microtubule associated parameters as predictive markers of docetaxel activity in advanced breast Cancer Patients: results of a pilot study. *Clin breast Cancer*, Dec 3, (5), 341- 345, 2003.
54. Granda T.G., D'Attino R.M., Filipski E., Vrignaud P., Garufi C., Terzoli E., Bissery M.C., and Lévi F. Rythme d'expression de la protéine BCL-2 chez la souris porteuse de tumeurs de l'adénocarcinome mammaire MA13/C, *Pathologie Biologie*, 51, 220- 221, 2003.
55. Granda T.G., Filipski E., Vrignaud P., Bissery M.C., and Lévi F.. Rhythm of expression of BCL-2 protein of MA13/C mammary adenocarcinoma bearing-mice. *Pathologie biologie*, 51, 220-221, 2003.

56. Galaup, A., Opolon, P., Bouquet, C., Li, H., Opolon, D., Bissery, MC, Tursz, T., Perricaudet, M., Griscelli, F., Combined effect of docetaxel and angiostatin gene therapy in prostate tumor model, *Molecular Therapy*, 7 (6), 731-740, 2003.
57. Kraus, L.A., Samuel, S.K., Schmid S.M., Dykes, D.J., Waud, W.R., Bissery, M.C. The mechanism of action of docetaxel (Taxotere®) in xenograft models is not limited to bcl-2 phosphorylation. *Investigational New Drugs*, (3):259-68, 2003.

Yoo, G.H., Piechocki, M.P., Ensley, J.F., Oliver, J., Kewson, D., Lonardo, F., Lin, H.S., Shibuya, T.Y., Kim H., Bissery, M.C. XRP6258 Induced Gene Expression Patterns in Head and Neck Cancer Carcinoma. *Submitted Cancer Research* 2003.

Bissery, M.C., Vrignaud, P., Veitia, R., Lavelle, F., Campone, M., Fumoleau, P., and Fellous, A. Docetaxel and Vinorelbine combination chemotherapy : antitumor efficacy and mechanism of action, *in preparation*.

c) Book chapters

1. Thies, C. Bissery, M.C. Biodegradable Microspheres for Parenteral Administration. In: *Biomedical Applications of Microencapsulation*, F. Lim, editor, CRC Press, Boca Raton, Florida, pp. 53-74, 1984.
2. Bissery, M.C., Valeriote, F. and Thies, C. In Vitro and In Vivo Evaluation of CCNU-loaded Microspheres Prepared from Poly (D,L) Lactide and Poly-beta-Hydroxybutyrate. In: *Microspheres and Drug Therapy*, Davis, Illum, McVie and Tomlinson editors, Elsevier Biomedical Press, Amsterdam, The Netherlands, pp. 217-227, 1984.
3. Bissery, M.C. De l'utilisation de méthodes in vitro et in vivo dans la recherche de nouvelles molécules anticancéreuses. In : *Les progrès des modèles biologiques dans la recherche expérimentale*, XIèmes Journées d'Etude Iffa-Credo, collection Fondation Marcel Mérieux, Lyon, France, pp 91-97, 1991.
4. Bissery, M.C. et al. Anticancer agents in development at Rhône-Poulenc Santé. In : *Cytotoxic anticancer drugs : models and concepts for drug discovery and development*, Valeriote, Corbett and Baker editors, Kluwer Academic Publisher, Boston, USA, pp 403-409, 1992.
5. Corbett, T.H., Polin, L., Panchapor, C., Pugh, S., White, K., Lowichik, N., Bissery, M.C., Wozniak, A., LoRusso, P., Biernat, L., Polin, D., Knight, J., Knight, L., Biggar, S., Looney, D., Demchik, L., Jones, J., Essenmacher, S., Lisow, L., Mattes, K., Cavanaugh, P., Rake, J., Baker, L., and Valeriote, F.A., Discovery of solid tumor active agents using a soft-agar-colony-formation disk-diffusion-assay. In : *Cytotoxic anticancer drugs : models and concepts for drug discovery and development*, Valeriote, Corbett and Baker editors, Kluwer Academic Publisher, Boston, USA, pp 35-87, 1992.
6. Bissery, M.C., and Armand, J.P. Pre-clinical in vitro screening of chemotherapeutic agents. In : *Handbook of Chemotherapy in Clinical Oncology*, J.P. Armand, E. Cvitkovic, J.P. Droz and S. Khoury editors, pp 50-57, 1993.
7. Bissery, M.C., Burris, H., and Pazdur, R. Preclinical pharmacology and phase I clinical trials of Taxotere® (RP 56976, NSC 628503). In: *Cytotoxic anticancer drugs: models and concepts for drug discovery and development*, Valeriote, Corbett and Baker editors, Kluwer Academic Publisher, Boston, USA, pp 283-297, 1994.
8. Ojima, I., Park, Y.H., Fenoglio, I., Duclos, O., Sun, C.-M., Kuduk, S.C., Zucco, M., Appendino, G., Pera, P., Veith, J.M., Bernacki, R.J., Bissery, M.C., Combeau, C., Vrignaud, P., Riou, J.F., and Lavelle, F. Synthesis and structure-activity relationships of new taxoids. In "Taxane Anticancer Agents : Basic Science and the Current Status"; Georg, G.I.; Chen, T.T.; Ojima, I., Vyas, D.M. (Eds.); ACS Symp Series, American Chemical Society, Washington, D.C.; pp 262-275, 1994.
9. Chabot, G.G., de Forni, M., Abigeres, D., Armand, J.P., Clavel, M., Bugat, R., Culine, S., Extra Marty, M., Bissery, M.C., Mathieu-Boué, A., Hérait, P., and Gouyette, A. Clinical tria^r pharmacology studies of CPT-11 and its active metabolite SN-38 in France: Pr

pharmacokinetic-pharmacodynamic relationships. In: Camptothecins: new anticancer agents. M. Potmesil and H. Pinedo, editors, CRC Press, Inc., Boca Raton, Florida, USA, pp. 83-91, 1995.

10. Bissery, M.C., Vrignaud, P., Lavelle, F. *In vivo* evaluation of docetaxel (Taxotere) and vinorelbine (Navelbine) as single agents and in combination in mammary tumor models. *Breast Cancer. Advances in Biology and Therapeutics*. F. Calvo, M. Crepin, H. Magdelenat, eds. John Libbey Eurotext, pp265-272, 1996.
11. Bissery, M.C., and Lavelle, F. Book Chapter. The Taxoids. In: *Cancer Therapeutics: Experimental and Clinical Agents*. B. Teicher Editor, Humana Press, Inc., Totowa, New Jersey, pp 175-193, 1997.
12. Mailliet P., Laoui A., Bourzat J.-D., Capet M., Commerçon A., Dereu N., LeBrun A. Martin J.P., Peyronel J.-F., Salagnad C., Thompson F., Zucco M., Guitton J.-D., Pantel G., Bissery M.-C., Brealey C., Lavayre J., Lelièvre Y., Riou J.-F., Vrignaud P., Duchesne M., and Lavelle F. From random screening of chemical libraries to the optimization of FPP-competitive inhibitors of farnesyl transferase. In *Farnesyltransferase Inhibitors in Cancer Chemotherapy*, 2000, Ch 9, p 115-144, edited by Said Sebti and Andrew Hamilton, Vol 8 in the series "Cancer Drug Discovery and Development" edited by Beverly A Teicher at Humana Press

d) Theses

1. Bissery, M.C. Les microsphères pour embolisation: sort dans l'organisme (Microspheres for chemoembolisation: in vivo disposition). Thèse de Doctorat d'exercice en pharmacie, Université de Paris XI, France, 56 pages, 1981.
2. Bissery, M.C. Formulation et caractérisation de microsphères pour chimio-embolisation (Formulation and characterization of microsphere for chemoembolization). Mémoire de Diplôme d'Etudes Approfondies de Pharmacie Industrielle et de Biopharmacie, Université de Paris XI, France, 39 pages, 1983.
3. Bissery, M.C. Formulation et caractérisation de microsphères pour chimiothérapie anticancéreuse et évaluation thérapeutique dans la leucémie AKR et le carcinome pulmonaire de Lewis chez la souris (Formulation and characterisation of anticancer drug loaded microspheres, and their evaluation in AKR leukemia and in Lewis lung carcinoma). Thèse de Doctorat ès Sciences Pharmaceutiques, Université de Paris XI, France, 284 pages, 1984.

e) Abstracts

1. Bissery, M.C., Puisieux, F. and Thies, C. Characterization of CCNU-loaded Poly-beta-Hydroxybutyrate) Microspheres. Article in: *Proceedings of the 9th International Symposium of Controlled Release*, Miami, Florida, pp. 30-31, 1982.
2. Bissery, M.C., Thies, C. and Puisieux, F. A Study of Process Parameters in the Making of Microspheres by the Solvent Evaporation Process. Article in: *Proceedings of the Troisième Congrès International de Technologie Pharmaceutique*, Paris, Vol. III, pp. 233-235, 1983.
3. Bissery, M.C., Thies, C. and Puisieux, F. A Study of Process Parameters in the Making of Microspheres by the Solvent Evaporation Process. Article in: *Proceedings of the 10th International Symposium of Controlled Release*, San Francisco, California, pp. 262-265, 1983.
4. Bissery, M.C., Thies, C. and Valeriote, F. In Vitro Drug Release from Poly-beta-Hydroxybutyrate and Poly (d,l) Lactide Microspheres, *Proc. 11th International Symposium of Controlled Release*, Miami, Florida, pp. 25-26, 1984.
5. Bissery, M.C., Valeriote, F. and Thies, C. Fate and Effect of CCNU-Loaded Microspheres Made of Poly (D,L) Lactide or Poly-beta-Hydroxybutyrate in Mice. *Proc. of the 12th International Symposium of Controlled Release of Bioactive Materials*, Geneva, Switzerland, pp. 181-182, 1985.
6. Benoit, J.P., Bissery, M.C. Cavalier, M., Puisieux, F., Linek, F., Bennett, J. and Thies, C. Solvent Evaporation Encapsulation Process. *American Chemical Society, 185th National Meeting*, Seattle, Wash., March 20-25, 1983.

7. Bissery, M.C., Valeriote, F. and Thies, C. In Vitro and In Vivo Evaluation of CCNU-loaded Microspheres Prepared from Poly (d,l) Lactide and Poly-beta-Hydroxybutyrate Microspheres. Microspheres Drug Therapy Conference, Amsterdam, The Netherlands, p. 32, October 31 - November 1-2, 1983.
8. Bissery, M.C., Puisieux, F., Summerfield, S., Lenk, T. and Thies, C. Preparation and Characterisation of Biodegradable Microsphere Fabricated from Beta-Hydroxybutyrate- Hydroxyvalerate Copolymers, Biointeractions '84 - Materials/Interactions London, U.K., p.13, January 4-6, 1984.
9. Bissery, M.C. and Valeriote, F. Microencapsulation of Anticancer Drug: In Vitro and In Vivo Study. Wayne State University Graduate Research Symposium, Detroit, MI, March 28, 1984.
10. Bissery, M.C., Valeriote, F. and Thies, C. Cytotoxicity of CCNU-loaded Microspheres Prepared from Poly (d,l) Lactide or Poly-beta-Hydroxybutyrate against AKR Leukemia. Proc. of the 75th Annual Meeting of the American Association for Cancer Research, Abstract No. 1452, p. 366, Toronto, Canada, May 9-11, 1984.
11. Bissery, M.C., Valeriote, F., Thies, C. Therapeutic Efficacy Of CCNU Loaded Microspheres Prepared From Poly (D,L) Lactide (PLA) or Poly-beta-Hydroxybutyrate (PHB) Against Lewis Lung Carcinoma. Proc. of the 76th Annual Meeting of The American Association For Cancer Research, Abstract No. 1400 p. 355, Houston TX, May 22-25, 1985.
12. Corbett, T.H., Bissery, M.C., Wozniak, A and Chabot, G.G. Flavone Acetic Acid (FAA): An Agent With Borad Solid Tumor Activity, American Society for Clinical Pharmacology and Therapeutics, March, 1986.
13. Corbett, T.H., Bissery, M.C., Wozniak, A., Plowman, J., Polin, L., Tapazoglou, E., Dieckman, J. and Valeriote, F. Solid Tumor Activity of Flavone Acetic Acid (FAA). Proc. of the 77th Annual Meeting of the American Association For Cancer Research. Abstract No. 1116 p. 281, Los Angeles May 7-10, 1986.
14. Bissery, M.C., Chabot, G.G., Corbett, T.H. and Rutkowski, K. Flavone Acetic Acid (FAA, NSC347512): Nonlinearity of Area Under the Concentration Time Curves With Changing Dosage. Proc. of the 77th Annual meeting of the American Association For Cancer Research. Abstract No. 1117 p. 282, Los Angeles May 7-10, 1986.
15. Chabot, G.G., Bissery, M.C., Corbett, T.H. and Rutkowski, K. Flavone Acetic Acid (FAA) (NSC347512) Pharmacokinetics In Mice. Proc. of the 77th Annual Meeting of the American Association for Cancer Research. Abstract No. 1615, pg. 407, Los Angeles, May 7-10, 1986.
16. Bissery, M.C., Corbett, T.H., Chabot, G.G., De Neve, W., Crissman, J.D., Yost, C. and Valeriote, F.A. Flavone Acetic Acid (NSC 347512)-Induced DNA Damage in Glasgow Osteogenic Sarcoma In Vivo. Proc. of the 78th Annual Meeting of the American Association for Cancer Research. Abstract No. 8, pg. 2, Atlanta, GA, May, 1987.
17. Chabot, G.G., Bissery, M.C., Corbett, T.H. and Rutkowski, K. Causes of the Nonlinear Pharmacokinetics of Flavone Acetic Acid (FAA, NSC-347512) in Mice. Proc. of the 78th Annual Meeting of the American Association for Cancer Research. Abstract No. 1730, pg. 436, Atlanta, GA, May, 1987.
18. Corbett, T., Bissery, M., Wozniak, A., LoRusso, P. and Polin, L. Toxicity of Solid Tumor Selective Agents. Proc. of the 78th Annual Meeting of the American Association for Cancer Research. Abstract No. 1696, pg. 428, Atlanta, GA, May, 1987.
19. Evelhoch, J.L., Bissery, M.C., Keller, N.A. and Corbett, T.H. Flavone Acetic Acid (FAA, NSC-347512)-Induced Reduction of ATP in Glasgow Osteogenic Sarcomas Monitored by In Vivo ³¹P Nuclear Magnetic Resonance (NMR) Spectroscopy. Proc. of the 6th Annual Meeting of the Society of Magnetic Resonance In Medicine. New York, NY, August, 1987.
20. Bissery, M.C., Wozniak, A.J., Heilbrun, L., and Corbett, T.H. Evaluation of Synthetic Agents by a Selective Multiple Tumor Soft Agar Assay. Proc. of the 79th Annual Meeting of the American Association for Cancer Research. Abstract No. 1955, New Orleans, LA, May, 1988.

21. Wozniak, A.J., Bissery, M.C., Biggar, S., Heilbrun, L., and Corbett, T.H. Comparison of Antitumor Activity of Fermentation Products in Murine Tumor Models and Human Tumor Lines. Proc. of the 79th Annual Meeting of the American Association for Cancer Research. Abstract No. 1953, New Orleans, LA, May, 1988.
22. Corbett, T.H., Polin, L., Wozniak, A.J., Bissery, M.C., LoRusso, P.M., Valeriote, F.A., and Baker, L.H. The Use of a Multiple-Tumor-Soft-Agar -Disk-Diffusion-Assay to Detect Agents with Selective Solid Tumor Activity. Proc. of the 79th Annual Meeting of the American Association for Cancer Research. Symposium III: New Approaches to the Discovery of Anticancer Agents, New Orleans, LA, May, 1988.
23. Bissery, M.C., White, K., Polin, L., Puzycki, D., Zalupski, M.M. and Corbett, T.H. Murine Solid Tumor Activity of Vinzolidine. Proc. of the 79th Annual Meeting of the American Association for Cancer Research. Abstract No. 1325, New Orleans, LA, May, 1988.
24. LoRusso, P.M., Bissery, M.C., Polin, L., White, K. and Corbett, T.H. NSC 320846 (Bayer): A Novel Agent with Solid Tumor Selectivity. Proc. of the 79th Annual Meeting of the American Association for Cancer Research. Abstract No. 1332, New Orleans, LA, May 1988.
25. Evelhoch, J.L., Bissery, M.C., Chabot, G.G., Simpson, N.E., McCoy, C.L. and Corbett, T.H. Flavone Acetic Acid (NSC 347512)-Induced Modulation of Tumor Physiology Monitored by In Vivo NMR Spectroscopy. Proc. of the 79th Annual Meeting of the American Association for Cancer Research. Abstract No. 1995, New Orleans, LA, May 1988.
26. Bissery, M.C. Modèles de criblage des drogues anti-tumorales. Colloque de la société française de cancérologie, October 1988.
27. Bissery, M.C., Wozniak, A.J. and Corbett, T.H. Comparison of the use of murine and human tumors in the selection process of new anticancer agents. Proc. of the 6th NCI-EORTC symposium on new drugs in cancer therapy. Abstract 028, Amsterdam, March 1989 and, Invest. New Drugs, 7:355, 1989.
28. Corbett, T.H., Berthelon, J.P., Briet, P., Aristoff, P., Polin, L., Wozniak, A., Bissery, M.C., and Paull, K. Flavone Acetic Acid (FAA, NSC-347512): Efforts to overcome deficiencies with improved analogs. Proc. of the 6th NCI-EORTC symposium on new drugs in cancer therapy. Abstract 069, Amsterdam, March 1989.
29. Bissery, M.C., Bayssas, M. and Lavelle, F. Solid tumor activity of RP 49532, a marine antitumor agent. Proc. of the 80th Annual Meeting of the American Association for Cancer Research. Abstract No. 2308, San Francisco, CA, May 1989.
30. Bissery, M.C. et Corbett, T.H. Méthodes de criblage d'agents sélectifs envers les tumeurs solides. IXème Forum de Cancérologie, June 1989.
31. Bissery, M.C. and Corbett, T.H. The Use of a Multiple Tumor Soft Agar Assay To Screen Solid Tumor Selective Agents. Cancer Communication 3:No. 8-9, 303, October 1989.
32. Bissery, M.C. Strategies for new drug discovery and antitumor agents in development. 22nd Annual Cancer Symposium book on Anticancer Drug Discovery and Development-1, Detroit, MI, April 1990.
33. Bissery, M.C., Bayssas, M. and Lavelle, F. Preclinical evaluation of intravenous Taxotere® (RP56976, NSC 628503), a taxol analog. Proc. of the 81st Annual Meeting of the American Association for Cancer Research. Abstract No. 2475, Washington D.C., May 1990.
34. Bissery, M.C., Nguyen, C.H., Bisagni, E. and Lavelle, F. Preclinical evaluation of RP60475, a pyrido-benzo-indole antitumor agent. Proc. of the 81st Annual Meeting of the American Association for Cancer Research. Abstract No. 2474, Washington D.C., May 1990.
35. Lavelle, F., Nguyen, C.H., Bissery, M.C., Riou, J.F. and Bisagni, E. Structure-activity relationships in the pyrido-benzo-indole series, a new class of antitumor agents.. Proc. of the 81st Annual Meeting of the American Association for Cancer Research. Abstract No. 2476, Washington D.C., May 1990.

36. Mailliet, P., Barreau, M., Baudoin, B., Gontier, S., Lieure, P., Lavelle, F., Bissery, M.C., LePecq, J.B., Segal-Bendirdjian, E., and Chottard, J.C. Spiro((bridged bi or tricycloalkyl) ethylenediamine) platinum complexes; New promising platinum derivatives with lack of cis-DDP cross-resistance. Sixth International Symposium on Platinum and other metal coordination compounds in Cancer Chemotherapy, San Diego, CA, January 1991.
37. Bissery, M.C., Renard, A., Montay, G., Bayssas, M., and Lavelle, F. Taxotere®: Antitumor activity and pharmacokinetics in mice. Proc. of the 82nd Annual Meeting of The American Association For Cancer Research, Abstract No. 2386, Houston TX, May 15-18, 1991.
38. Bissery, M.C., Mathieu-Boué, A. and Lavelle, F. Preclinical evaluation of CPT-11, a camptothecin derivative. Proc. of the 82nd Annual Meeting of The American Association For Cancer Research, Abstract No. 2389, Houston TX, May 15-18, 1991.
39. Lavelle, F., Nguyen, C.H., Bissery, M.C., Riou, J.F. and Bisagni, E. Synthesis and antitumor properties of the pyrido-benzo-indole series. Proc. of the 82nd Annual Meeting of The American Association For Cancer Research, Abstract No. 2411, Houston TX, May 15-18, 1991.
40. Bissery, M.C., André, S., Renard, A., Montay, G., Bayssas, M., and Lavelle, F. RP 60475, a new antitopoisomerase II agent : present status of development. ARTAC : 4th International Workshop on Therapeutic Trials in Cancer and AIDS, Abstract 0.33, Paris, September, 1991.
41. Mathieu-Boué, A., Chabot, G., Bissery, M.C., Herait, P., Cote, C., Armand, J.P., Bugat, R., Clavel, M., and Marty, M. Preclinical and early clinical data of CPT-11, a new camptothecin analogue with antitopoisomerase I action. ARTAC : 4th International Workshop on Therapeutic Trials in Cancer and AIDS, Abstract 0.34, Paris, September, 1991.
42. Bissery, M.C., Riou, J.F., André, S., Bayssas, M. and Lavelle, F. Preclinical evaluation of RP 60475, a pyrido-benzo-indole antitumor agent. Proc. of ECCO6 meeting, Abstract No. 1890, Firenze, October, 1991.
43. De Forni, M., Culine, S., Barilero, I., Chabot, G., Bissery, M.C., Madelaine, I., Bugat, R., Marty, M. and Mathieu-Boué, A. Phase 1 Trial of the camptothecin analog CPT-11 administered as a weekly infusion. Proc. of ECCO-6 meeting, Abstract No. 1185, Firenze, October, 1991.
44. Gandia, D., Chabot, G., Barilero, I., Abigeres, D., Bissery, M.C., Carde, P., Gouyette, A., Mathieu-Boué, A. and Armand, J.P. Phase 1 study of CPT-11 administered every three weeks. Proc. of ECCO-6 meeting, Abstract No. 1242, Firenze, October, 1991.
45. Mailliet, P., Barreau, M., Baudoin, B., Gontier, S., Lieure, P., Lavelle, F., Bissery, M.C., Le Pecq, J.B., Segal-Bendirdjian, E., and Chottard, J.C. Spiro ((bridged bi or tricycloalkyl) ethylenediamine) platinum complexes : new promising platinum derivatives with lack of cis-DDP cross-resistance. Proc. of the 6th International Symposium on Platinum and other Metal Coordination Compounds in Cancer Chemotherapy, Abstract No. P-219, San Diego, CA, USA, 1991.
46. Bissery, M.C., Mathieu-Boué, A., and Lavelle, F. Experimental antitumor activity of CPT-11 in vitro and in vivo. Proc. of 7th NCI/EORTC Symposium, Abstract No. 093, Amsterdam, the Netherlands, 17-20th March 1992.
47. Clavel, M., Chabot, G., Dumortier, A., Cote, C., Talon, A., Foy, M., Bissery, M.C., and Mathieu-Boué, A. Phase I study of the camptothecin analogue CPT-11, administered daily for 3 consecutive days. Proc. of 7th NCI/EORTC Symposium, Abstract No. 097, Amsterdam, the Netherlands, 17-20th March 1992.
48. Mailliet, P., Chottard, J.C., Lambert, B., Segal-Bendirdjian, E., Fichtinger-Schepman, A.M., Yeung, A., Barreau, M., Bissery, M.C., Lavelle, F. and Le Pecq, J.B. Pharmacological and antitumoral properties of spiro ((bridged bi or tricycloalkyl) ethylene-diamine) platinum complexes. Proc. of 7th NCI/EORTC Symposium, Abstract No. 135, Amsterdam, the Netherlands, 17-20th March 1992.

49. Bissery, M.C., André, S., Renard, A., Montay, G., Bayssas, M., and Lavelle, F. Preclinical pharmacology and toxicology of RP 60475, a new benzo-pyrido-indole. Proc. of 7th NCI/EORTC Symposium, Abstract No. 143, Amsterdam, the Netherlands, 17-20th March 1992.
50. Armand, J.P., Chabot, G.G., Marty, M., Clavel, M., De Forni, M., Bugat, R., Herait, P., Bissery, M.C., and Mathieu-Boué, A. The french clinical experience during three phase I studies with the camptothecin analogue CPT-11, a new topoisomerase I inhibitor. Proc. of 7th NCI/EORTC Symposium, Abstract No. 238, Amsterdam, the Netherlands, 17-20th March 1992.
51. Harrison, S.D., Dykes, D.J., Bissery, M.C., and Griswold, D.P. Response of four human tumor xenografts in nude mice to Taxotere®. Proc. of 7th NCI/EORTC Symposium, Abstract No. 250, Amsterdam, the Netherlands, 17-20th March 1992.
52. Bissery, M.C., Renard, A., André, S., Montay, G., Le Bail, N., Bayssas, M., and Lavelle, F. Preclinical pharmacology and toxicology of RP Taxotere® (RP 56976, NSC 628503). Proc. of 7th NCI/EORTC Symposium, Abstract No. 251, Amsterdam, the Netherlands, 17-20th March 1992.
53. Vogel, M., Danhauser-Riedl, S., Block, T., Necarda, H., Fellbaum, Ch., Dietzfelbinger, H., Bissery, M.C., Rastetter, J., Hanauske, A.R. Preclinical activity of Taxotere® (RP 56976, NSC 628503) and taxol against human tumor colony forming units. Proc. of 7th NCI/EORTC Symposium, Abstract No. 255, Amsterdam, the Netherlands, 17-20th March 1992.
54. Bissery, M.C., André, S., Le Bail, N., Bayssas, M., Riou, J.F., and Lavelle, F. Taxotere® (RP 56976, NSC 628503) : present status of development. Second interface of clinical and laboratory responses to anticancer drugs : drugs and microtubule, Marseille, France, Avril 2-4, 1992, vol 1, p 510.
55. Clavel, M., Mathieu-Boué, A., Dumortier, A., Chabot, G.G., Cote, C., Bissery, M.C., and Marty, M. Phase I study of CPT-11 administered as a daily infusion for 3 consecutive days. Proc. of the 83rd Annual Meeting of the American Association for Cancer research, Vol 33, Abstract No. 1568, San Diego, USA, May, 1992.
56. Riou, J.F., Fossé, P., Bissery, M.C., Larsen, A.K., Nguyen, C.H., Grondard, L., Saucier, J.M., Bisagni, E., and Lavelle, F. RP-60475 and derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities. Proc. of the 83rd Annual Meeting of the American Association for Cancer research, Vol 33, Abstract No. 2611, San Diego, USA, May, 1992.
57. Bissery, M.C., Vrignaud, P., Bayssas, M., and Lavelle, F. In vivo evaluation of Taxotere® (RP 56976, NSC 628503) in combination with cisplatin, doxorubicin, or vincristine. Proc. of the 83rd Annual Meeting of the American Association for Cancer research, Vol 33, Abstract No. 2645, San Diego, USA, May, 1992.
58. Fromes, Y., Gounon, P., Bissery, M.C., and Fellous, A. Differential effects of taxol and Taxotere® (RP 56976, NSC 628503) on Tau and MAP2 containing microtubules. Proc. of the 83rd Annual Meeting of the American Association for Cancer research, Vol 33, Abstract No. 3055, San Diego, USA, May, 1992.
59. Vogel, M.M., Danhauser-Riedl, S., Block, T., Necarda, H., Fellbaum, Ch., Dietzfelbinger, H.F., Bissery, M.C., Aapro, M., Rastetter, J., Hanauske, A.R. Preclinical activity of Taxotere® (RP 56976) and taxol against human tumor colony forming units. Proc. of the 83rd Annual Meeting of the American Association for Cancer research, Vol 33, Abstract No. 3115, San Diego, USA, May, 1992.
60. Harrison, S.D., Jr., Dykes, D.J., Shepherd, R.V., Griswold, D.P., Jr., and Bissery, M.C. Response of human tumor xenografts to Taxotere®. Proc. of the 83rd Annual Meeting of the American Association for Cancer research, Vol 33, Abstract No. 3144, San Diego, USA, May, 1992.
61. Bissery, M.C., Renard, A., Montay, G., and Lavelle, F. Efficacy, pharmacokinetics and distribution of RP 60475. Proc. of the 83rd Annual Meeting of the American Association for Cancer research, Vol 33, Abstract No. 3188, San Diego, USA, May, 1992.
62. Armand, J.P., Bissery, M.C., Chabot, G.G., de Forni, M., Bugat, R., Marty, M., Clavel, M., Mathieu-Boué, A., Hérait, P. The French experience of CPT-11 phase I studies: Which optimal regimen for phase II

- recommendation. Fifth World Conference of Clinical Pharmacology and Therapeutics. Satellite Symposium: "Approaches to Cancer Treatment by Topoisomerase I Inhibitors". Tokyo, Japan, July 25, 1992.
63. Bissery, M.C., Vrignaud, P., Bayssas, M., Lavelle, F. Combination chemotherapy of RP 56976 with etoposide, cyclophosphamide and 5-fluorouracil. *Proc. Amer. Assoc. Cancer Res.*, vol 34, abstract 1782, 1993.
 64. Eckardt, J., Burris, H., Klink Alakl, M., Bissery, M.C., Von Hoff, D.D. Intoplicine (RP 60475): preclinical studies of a new topoisomerase I and II inhibitor. *Proc. Amer. Assoc. Cancer Res.*, vol 34, abstract 2611, 1993.
 65. Bissery, M.C. Preclinical evaluation of Taxotere® (docetaxel, RP 56976). ECCO-7, A new generation taxoid compounds, Satellite Symposium, Jerusalem, Israel, 1993.
 66. Bissery, M.C. Evaluation précliniques des associations chimiothérapeutiques. Stratégie des thérapeutiques innovantes. Deuxième colloque de recherche clinique, 6 et 7 décembre 1993, Paris.
 67. Massaad, L., Chabot, G.G., Bissery, M.C., Toussaint, C., Albin, N., Parise, O., Morizet, J., Gouyette, A. Influence de la croissance tumorale sur les principales enzymes impliquées dans la biotransformation des xénobiotiques dans la tumeur colique murine colon 38. Treizième Forum de Cancérologie, Paris, 14-16 juin 1993, *Bulletin du Cancer*, vol. 80, p. 527, 1993.
 68. Commerçon, A., Bourzat, J.D., Bouchard, H., Didier, E., Fouque, E., Bissery, M.C., Combeau, C., Riou, J.F., Vrignaud, P., Lavelle, F. Preparation and biological evaluation of docetaxel analogues modified on the 3'-phenyl ring. American Chemical Society National Meeting, San Diego, 1994.
 69. Commerçon, A., Bourzat, J.D., Didier, E., Fouque, E., Bissery, M.C., Vrignaud, P., Riou, J.F., Lavelle, F. Practical synthesis of docetaxel and its analogues. American Chemical Society National Meeting, San Diego, 1994.
 70. Bissery, M.C., Bourzat, J.D., Commerçon, A., Frydman, A., Gaillard, C., Lavel, F., Monegier, D., Sable, S., Vuilhorgne, M. Isolation, identification, synthesis, and biological activities of docetaxel metabolites. 207th American Chemical Society Annual Meeting, San Diego, Medi:144, 1994.
 71. Lorusso, P.M., Demchik, L., Knight, J., Bissery, M.C., Polin, L., Leopold, W.R., Corbett, T.H. Preclinical antitumor activity of acetyldinaline. Eighth NCI-EORTC Symposium on New Anticancer Drugs, Amsterdam, March 14-18, 1994. *Annals of Oncology* vol. 5, Suppl. 5, p. 95, abstract 105, 1994.
 72. Vassal, G., Morizet, J., Bissery, M.C., Bénard, J., Boland, I., Ardouin, P., Mathieu-Boué, A., Gouyette, A. Activity of the camptothecin analogue CPT-11 (irinotecan) against neuroblastoma xenografts. Eighth NCI-EORTC Symposium on New Anticancer Drugs, Amsterdam, March 14-18, 1994. *Annals of Oncology* vol. 5, Suppl. 5, p. 189, abstract 456, 1994.
 73. Commerçon, A., Bourzat, J.D., Bouchard, H., Bissery, M.C., Combeau, C., Riou, J.F., Vrignaud, P. and Lavelle, F. Synthesis and biological properties of docetaxel analogs modified on the side chain. Eighth NCI-EORTC Symposium on New Anticancer Drugs, Amsterdam, March 14-18, 1994. *Annals of Oncology* vol. 5, Suppl. 5, p. 200, abstract 501, 1994.
 74. Bourzat, J.D., Bouchard, H., Commerçon, A., Bissery, M.C., Combeau, C., Vrignaud, P., Riou, J.F., Lavelle, F. Preparation and biological evaluation of new docetaxel analogs modified at the 3'-position of the side-chain. Eighth NCI-EORTC Symposium on New Anticancer Drugs, Amsterdam, March 14-18, 1994. *Annals of Oncology* vol. 5, Suppl. 5, p. 201, abstract 502, 1994.
 75. Commerçon, A., Bourzat, J.D., Bouchard, H., Bissery, M.C., Combeau, C., Riou, J.F., Vrignaud, P. and Lavelle, F. Synthesis and biological properties of docetaxel analogs modified on the side chain. Eighty-fifth Annual Meeting of the American Association for Cancer Research, San Francisco, April 10-13, 1994. *Proceedings of the American Association for Cancer Research*, vol. 35, p. 400, abstract 2383, 1994.
 76. Bissery, M.C., Vrignaud, P., Bayssas, M. and Lavelle, F. Docetaxel (RP 56976, Taxotere®) efficacy as a single agent or in combination against mammary tumors in mice. Eighty-fifth Annual Meeting of the

- American Association for Cancer Research, San Francisco, April 10-13, 1994. Proceedings of the American Association for Cancer Research, vol. 35, p. 327, abstract 1946, 1994.
77. Vrignaud, P., Lavelle, F., and Bissery, M.C. *In vivo* chemosensitivity of a P388 murine leukemia resistant to camptothecin. Eighty-fifth Annual Meeting of the American Association for Cancer Research, San Francisco, April 10-13, 1994. Proceedings of the American Association for Cancer Research, vol. 35, p. 363, abstract 2160, 1994.
 78. Fellous, A., Fromes, Y., Garret, S., Mazie, J.C., Bissery, M.C. Docetaxel sensitive and insensitive mammary adenocarcinomas contain different polypeptides related to brain MAP-2 protein. Proceeding of the American Association for Cancer Research, vol. 35, p. 385, abstract 2293, 1994.
 79. Lorusso, P.M., Demchik, L., Knight, J., Bissery, M.C., Polin, L., Leopold, W.R., Corbett, T.H. Preclinical antitumor activity of acetyldinaline. Eighty-fifth Annual Meeting of the American Association for Cancer Research, San Francisco, April 10-13, 1994. Proceedings of the American Association for Cancer Research, vol. 35, p. 401, abstract 2391, 1994.
 80. Chabot, G.G., Gouyette, A., Bissery, M.C. Tumor influence on pharmacokinetics of the camptothecin analogue irinotecan (CPT-11) and active metabolite SN-38 in mice. Eighty-fifth Annual Meeting of the American Association for Cancer Research, San Francisco, April 10-13, 1994. Proceedings of the American Association for Cancer Research, vol. 35, p. 432, abstract 2576, 1994.
 81. Vassal, G., Morizet, J., Bissery, M.C. Boland, I., Ardouin, P., Mathieu-Boué, A., Gouyette, A. Activity of the camptothecin analogue CPT-11 (irinotecan) against medulloblastoma xenografts. Eighty-fifth Annual Meeting of the American Association for Cancer Research, San Francisco, April 10-13, 1994. Proceedings of the American Association for Cancer Research, vol. 35, p. 366, abstract 2183, 1994.
 82. Vassal, G., Morizet, J., Bissery, M.C., Boland, I., Ardouin, P., Mathieu-Boué, A., Gouyette, A. Activity of the camptothecin analogue CPT-11 (irinotecan) against medulloblastoma xenografts. Sixth International Symposium on Pediatric Neuro-Oncology, Houston, USA, May 18-21 1994.
 83. Bissery, M.C., Vrignaud, P., Bayssas, M., Lavelle, F. Etude de l'activité du Taxotère en association chez la souris. 14ième Forum de Cancérologie, Paris, 30 Mai - 1er Juin 1994, Bulletin du Cancer, pp 556-557, vol. 81, 6, 1994.
 84. Chabot, G.G., Bissery, M.C. Influence de la tumeur sur la pharmacocinétique de l'analogue de la camptothécine Irinotécan (CPT-11) et de son métabolite actif SN-38 chez la souris. 14ième Forum de Cancérologie, Paris, 30 Mai - 1er Juin 1994, Bulletin du Cancer, p 561, vol. 81, 6, 1994.
 85. Vassal, G., Morizet, J., Bissery, M.C., Bénard, J., Boland, I., Ardouin, P., Mathieu-Boué, A., Gouyette, A. Activity of the camptothecin analogue CPT-11 (irinotecan) against neuroblastoma xenografts. International Society of Pediatric Oncology, Paris, September 20-24, 1994, Med. Ped. Oncol. 1994.
 86. Bourzat, J.D., Bouchard, H., Commerçon, A., Bissery, M.C., Combeau, C., Vrignaud, P., Riou, J.F., and Lavelle, F. Preparation and biological evaluation of new docetaxel analogs modified at the 3'-position of the side-chain. XVI International Cancer Congress, New Delhi, India, 30 October - 5 November 1994.
 87. Chabot, G., Bissery, M.C., and Gouyette, A. Influence de la tumeur sur la pharmacocinétique et le métabolisme de l'analogue de la camptothécine irinotecan (CPT-11) chez la souris. Cinquièmes Journées Francophones de Pharmacologie Clinique Oncologique, Reims, France, 9-10 Novembre 1994.
 88. Hittinger, A., André, S., Barreau, M., Bissery, M.C., Chottard, J.C., Commerçon, A., Gontier, S., Lavelle, F., Le Pecq, J.M., Mailliet, P., Riou, J.F., Toutain, H., Vrignaud, P. A new series of platinum (IV) complexes as potent antitumor agents in murine solid-tumor models after oral administration. 13th International Symposium on Medicinal Chemistry, p 248, 1994.
 89. Lavelle, F., Riou, J.F., Bissery, M.C., André, S., Roquet, F. Preclinical studies of CPT-11 and its active metabolite SN-38. Fifth International Congress on Anti-Cancer Chemotherapy (Neo-Adjuvant, Adjuvant and Experimental) Paris France, January 31-February 1-3, 1995.
 90. Bissery, M.C., Vrignaud, P., Riou, J.F., and Lavelle, F. *In vivo* isolation and characterization of π docetaxel resistant B16 melanoma. Proc. AACR, vol. 36 page 316, Abstract 1882, 1995.

91. Vrignaud, P., Selingue, A., Caillaud, J.M., Lavelle, F., Bissery, M.C. Characterization of tumors arising in transgenic MMTV/c-neu mice. Proc. AACR, vol. 36 page 187, Abstract 1116, 1995.
92. Tampellini, M., Filipinski, E., Bissery, M.C., Lévi, F. Circadian dosing time dependency of Taxotere (TXT) toxicity: implication for antitumor efficacy. Proc. AACR, vol. 36 page 455, Abstract 2713, 1995.
93. Fellous, A., Fromes, Y., Veitia, R., Mazie, J.C. and Bissery, M.C. Docetaxel sensitive and refractory pancreatic tumors contain different polypeptides related to brain microtubule associated proteins (MAP2). Proc. ASCO, vol. 14, p 87, Abstract 51, 1995.
94. Bissery, M.C., Vrignaud, P., Bayssas, M., Lavelle, F. Preclinical *in vivo* activity of docetaxel containing combinations. Proc. ASCO, vol. 14, p. 489, abstract 1599, 1995.
95. Vrignaud, P., Selingue, A., Caillaud, J.M., Lavelle, F., Bissery, M.C. Caractérisation d'un modèle de souris transgéniques MMTV/c-neu développant des tumeurs mammaires. 15e forum de cancérologie, Paris, 12-14 Juin 1995, Bulletin du Cancer, vol. 82, 6, p. 412, Abstract 119.
96. Transgénique SFEA Vrignaud 1996
97. Tampellini, M., Filipinski, E., Vrignaud, P., Bissery, M.C., Lévi, F. Circadian variations of docetaxel tolerability in mice: relationship with its antitumor efficacy. World Conference on Chronobiology and Chronotherapeutics, Ferrera (Italy), September 6-10, 1995. Biological Rhythm Research, vol. 26, 4, p. 447, Abstract 227, 1995.
98. Bissery, M.C., Vrignaud, P., Lavelle, F. Preclinical *in vivo* evaluation of docetaxel (Taxotere®) containing combinations. The Cytoskeleton and Cancer. Proc. of the Cytoskeleton and Cancer, Abstract p. 50. Ile des Embiez, France, 17-20 September 1995.
99. Bissery, M.C., Vrignaud, P., Lavelle, F. Preclinical antitumor activity and pharmacokinetics of irinotecan (CPT-11) in tumor-bearing mice. The Camptothecins: From the Discovery to the Patient. Annual New York Academy of Sciences Conference. Bethesda, USA, Feb 7-10, 1996.
100. Bissery, M.C., Vrignaud, P., Riou, J.F., Combeau, C., Chabot, C.G., Lavelle, F. *In vivo* development and characterization of a docetaxel-resistant B16 melanoma. 9th NCI-EORTC Symposium New Drugs in Cancer Therapy. Amsterdam, March 12-15, 1996, p. 94, Abstract 328.
101. Bissery, M.C., Vrignaud, P., Lavelle, F. *In vivo* evaluation of the docetaxel-irinotecan combination. Proc. AACR, vol. 37, Abstract 2578, March 1996.
102. Vrignaud, P., Selingue, A., Lavelle, F., Bissery, M.C. Chemosensitivity of mammary tumors arising in MMTV/c-neu transgenic mice. Proc. AACR, vol. 37, Abstract 3007, p. 440, March 1996.
103. Schmid, S.M., Coffield, R.T., Dykes, D.J., and Bissery, M.C. Docetaxel induction of S- and G2+M- phase accumulation and apoptosis *in vivo* with a human breast tumor model in mice. Proc. AACR, vol. 37, Abstract 2990, p. 438, March 1996.
104. Bissery, M.C., Azli, N., Fumoleau, P. Docetaxel in combination with vinorelbine: preclinical-clinical correlation. Proc. ASCO, vol. 14, Abstract 1550, p. 487, May 1996.
105. Peacock, N, Rodriguez, G., Smith, L., Fields, S., Cook, G., Bissery, M.C., Bellet, R., Von Hoff, D., Burris, H. A phase I study of Docetaxel (Taxotere) and 5-Fluorouracil combination chemotherapy in patients with advanced solid tumors. Proc. ASCO, vol. 14, Abstract 1562, p. 490, May 1996.
106. Vrignaud, P., Selingue, A., Lavelle, F., Bissery, M.C. Evaluation of docetaxel and doxorubicin in MMTV/c-neu transgenic mice bearing mammary tumors. Proc. sixth Felasa Symposium, Basel, Switzerland, June 19-21, 1996.
107. Bissery M.C., Vrignaud, P., Lavelle, F. Preclinical antitumor activity following oral administration of Irinotecan (CPT-11). Proc. of the 21st ESMO, Abstract 625P, p130, Vienna, November 1-5, 1996
108. Bissery M.C., Vrignaud, P., Lavelle, F. *In vivo* evaluation of oral Irinotecan (CPT-11).

109. Proc. seventh international congress on anticancer treatment, Abstract P262, p191, Paris, Feb 3-6, 1997
110. Vrignaud, P., Sounigo, F., Maillet, P., Duchesne, M., Lelièvre, Y., Bissery, M.C., Riou, J.F., Chevé, M., Chapelle, P., Tocqué, B., Commerçon, A., and Lavelle, F. RPR115135: *in vitro* and *in vivo* evaluation of a non-peptidomimetic farnesyl transferase inhibitor. AACR conference: Cell signaling and cancer treatment, Telfs-Buchen, Austria, Feb. 23-24, 1997.
111. Vrignaud, P., Maillet, P., Bissery, M.C., Duchesne, M., Lelièvre, Y., Riou, J.F., Chapelle, P., Tocqué, B., and Lavelle, F. Structure activity relationship and *in vivo* evaluation in a new promising family of nonpeptidomimetic farnesyltransferase inhibitors, 1997 AACR meeting.
112. Bissery, M.C., Vrignaud, P., Lavelle, F. Oral efficacy of irinotecan (CPT-11) in tumor bearing mice, 1997 AACR meeting.
113. Bissery, M.C., Couteau, C., Oulid-Aïssa, D., and Armand, J.P. Docetaxel in combination with Irinotecan: preclinical-clinical correlation, 1997 ASCO meeting.
114. Bissery, M.C., Vrignaud, P., Lavelle, F. *In vivo* evaluation of the irinotecan-oxaliplatin combination, 1997 ECCO 9 meeting.
115. Veitia, R., Bissery, M.C., Martinez, C., and Fellous, A. Tau overexpression in murine adenocarcinomas correlates with docetaxel sensitivity in tumor-bearing mice, 1998 AACR meeting.
116. Vrignaud, P., Bello, A., Bissery, M.C., Jenkins, R., Hasnain, A., Maillet, P., Lavelle, F. RPR 130401, a non-peptidomimetic farnesyltransferase inhibitor with *in vivo* activity, 1998 AACR meeting.
117. Chiron, M.F., Bissery, M.C., Attenot, F., and Virone-Oddos, A. Combination of Ad5CMV-p53 with docetaxel: additive cytotoxic effects in Non Small Cell Lung Carcinoma, 1998 AACR meeting.
118. Bissery, M.C., Vrignaud, P. and Lavelle, F. *In vivo* evaluation of the irinotecan-oxaliplatin combination, 1998 AACR meeting.
119. Solís Recéndez, M.G., Bichat, F., Barbault, H., Bissery, M.C*, Azli, N*, Khayat, D., Bastian, G. Drug interaction between taxotere (TXT) and adriamycin (ADR) in mice*: Tissue ADR incorporation according to the schedule of administration. 90th Annual Meeting of the American Association for Cancer Research, Philadelphia, April 10-14, #558, 40, 1999.
120. Veitia, R., Bissery, M.C., Barbier, P., Azoulay, S. and Fellous, A. Docetaxel acquired resistance in a human derived breast tumor is associated with alteration of class II and class IV [beta] tubulin expression and of [alpha] tubulin acetylation. 90th Annual Meeting of the American Association for Cancer Research, Philadelphia, April 10-14, #1883, 40, 1999.
121. Bissery M.C., Vrignaud P., Lejeune P., Lavelle F. Evaluation of anticancer agents against orthotopic and subcutaneous colon tumors. 90th Annual Meeting of the American Association for Cancer Research, Philadelphia, April 10-14, #2253, 40, 1999.
122. Vrignaud, P., Bissery, M.C., Maillet, P., Lavelle, F. *In vivo* combination of RPR 130401, a non-peptidomimetic farnesyltransferase inhibitor, with chemotherapy. 90th Annual Meeting of the American Association for Cancer Research, Philadelphia, April 10-14, #3453, 40, 1999.
123. Kraus, L.A., Schmid, S.M., Coffield, R.T., Kern, F., Samuel, S., Dykes, D.J., and Bissery, M.C. The mechanism of action of docetaxel and paclitaxel in xenograft models is not limited to Bcl-2 phosphorylation. 90th Annual Meeting of the American Association for Cancer Research, Philadelphia, April 10-14, #3809, 40, 1999.
124. Filipinski, E., Liu, X.H., Vrignaud, P., Bissery, M.C., and Lévi, F. Chronopharmacologic optimization of docetaxel-doxorubicin combination in mice with P388 leukemia. 90th Annual Meeting of the American Association for Cancer Research, Philadelphia, April 10-14, #3885, 40, 1999.
125. Virone-Oddos A., Adeline E., Bissery MC, Vrignaud P., Dubois MH, and Chiron MF. *In vivo* evaluation of docetaxel-Ad5CMV-p53 gene therapy combination in human non small cell lung carcinoma (NSCLC).

- 90th Annual Meeting of the American Association for Cancer Research, Philadelphia, April 10-14, #3928, 40, 1999.
126. Vrignaud P., Selingue A., Colombel S., d'Heilly S., Lavelle F, Bissery M.C.. Characterization of orthotopic colon tumor models for the evaluation of anticancer agents. 7th Felasa Symposium, Palma de Mallorca, May 26-28, 1999.
 127. Granda T.G., Filipski E., d'Attino R.M., Vrignaud P., Bissery M.C., Levi F. Rythme de tolérance à la doxorubicine chez la souris C3H/HeN : Prérequis pour une chronothérapie des cancers mammaires. 31^{ème} congrès annuel du groupe d'études des rythmes biologiques, Bordeaux, 10-12 mai, 1999.
 128. Mailliet P., Bourzat J.D., Capet M., Chevé M., Commerçon A., Dereu N., Laoui A., LeBrun A., Maignan S., Martin J.P., Peyronel J.F., Salagnad C., Thompson F., Zucco M., Guitton J.D., Bissery M.C., Brealey C., Debussche L., Duchesne M., Lelièvre Y., Riou J.F., Vrignaud, P. and Lavelle F. Benzo(f)perhydroisoindoles as farnesyl transferase inhibitors and their potential use as novel cytostatic drugs. The fourteenth French-Japanese Symposium on Medicinal and Fine Chemistry, La Baule, France, Sept. 19-23, 1999.
 129. M.C. Bissery, H. Bouchard, J.F. Riou, P. Vrignaud, C. Combeau, J.D. Bourzat, A. Commerçon, F. Lavelle. Preclinical evaluation of TXD258, a new taxoid. Proc. 91st AACR meeting, # 1364, April 1-5, 2000, San Francisco.
 130. P. Vrignaud, P. Lejeune, D. Chaplin, F. Lavelle, M.C. Bissery. *In vivo* efficacy of TXD258, a new taxoid, against human tumor xenografts. Proc. 91st AACR meeting, #1365, April 1-5, 2000, San Francisco.
 131. Y. Archimbaud, P. Gires, R. Pellerin, L. Ridoux, P. Vrignaud, D. Semiond, M.C. Bissery, and M. Marietta. Mouse plasma and tumor pharmacokinetics of TXD258, a new taxoid. Proc. 91st AACR meeting, # 1373, April 1-5, 2000, San Francisco.
 132. T. G. Granda, E. Filipski, R.M. D'Attino, P. Vrignaud, M.C. Bissery, and F. Lévi. Chronopharmacology of docetaxel and doxorubicin in mice with MA13/C mammary adenocarcinoma. Proc. 91st AACR meeting, # 1267, April 1-5, 2000, San Francisco.
 133. R.M. D'Attino, E. Filipski, T. Granda, P. Vrignaud, M.C. Bissery, J. Irinotecan (CPT-11) and oxaliplatin (I-OHP) synergistic activity at specific circadian times in tumor-bearing mice. Proc. 91st AACR meeting, # 1268, April 1-5, 2000, San Francisco.
 134. Dykes, D.J., Sarsat, J.P., Bissery, M.C. Efficacy Evaluation of TXD258, a Taxoid Compound, Against Orthotopic and Subcutaneous Glioblastomas. Proc. 91st AACR meeting, #1916, April 1-5, 2000, San Francisco
 135. Aller, A.W., Kraus, L.A., Bissery, M.C. *In Vitro* Activity of TXD258 in Chemotherapeutic Resistant Tumor Cell Lines. Proc. 91st AACR meeting, # 1923, April 1-5, 2000, San Francisco.
 136. Treilleux, I., Barbier, P., Fellous, A., Bissery, M.C., Peloux, N., Dumontet, C., and Di Leo, A.. Correlation between microtubule components and response to docetaxel in patients with metastatic breast cancer, Proc. 91st AACR meeting, # 3521, April 1-5, 2000, San Francisco.
 137. Wales, C., Barbier, P., Banerjee, M., Gosh-Choudhury, N., Bissery, M.C., Luduena, R.F., and Fellous, Nuclear Tubulin as a Possible Marker for Breast Cancer Cells. Proc. 91st AACR meeting, # 3522, April 1-5, 2000, San Francisco.
 138. P. Vrignaud, P. Lejeune, M.C. Bissery. TXD258, a new taxoid, with oral antitumor efficacy. 92nd Annual Meeting of the American Association for Cancer Research, New Orleans, March 24-28, #1975, 42, 2001.
 139. M.C. Bissery, P. Lejeune, P. Vrignaud. *In vivo* evaluation of irinotecan combinations. 92nd Annual Meeting of the American Association for Cancer Research, New Orleans, March 24-28, #479, 42, 2001.
 140. T. G. Granda, X.H. Liu, E. Filipski, P. Vrignaud, M.C. Bissery, and F. Lévi. Different rhythms in cell cycle distribution in bone marrow and in MA13/C mammary tumor of C3H/HeN mice. 92nd Annual Meeting of the American Association for Cancer Research, New Orleans, March 24-28, #4897, 42, 2001.

141. M.-C. Bissery, P. Lejeune, P. Vrignaud. The combination of Flavopiridol with Docetaxel (Taxotere®) is synergistic in a murine adenocarcinoma model MA13/C. Submitted, ASCO, Orlando, May, 2002
142. P. Vrignaud, P. Lejeune, R. E. Klem, M.-C. Bissery. Combination of G3139 (Genasense™), a bcl-2 antisense oligonucleotide, with docetaxel (Taxotere®) is active in a murine xenograft model of human non-small cell lung cancer. 93rd AACR meeting, San Francisco, April 6-10, #2865, 2002.
143. M.-C. Bissery, P. Lejeune, P. Vrignaud. In vivo evaluation of AVE8062A, a compound active on the tumor vasculature. 93rd AACR meeting, San Francisco, April 6-10, #780, 2002.
144. P. Lejeune, T. Hodge, P. Vrignaud, M.-C. Bissery. In vivo antitumor activity and tumor necrosis induced by AVE8062A, a tumor vasculature targeting agent. 93rd AACR meeting, San Francisco, April 6-10, #781, 2002.
145. Y. Archimbaud, M.C. Fraschini, R. Pellerin, P. Vrignaud, C.Veyrat-Follet, and M.C. Bissery. Mouse plasma and tumor pharmacokinetics of AVE8062 a new combretastatine. 93rd AACR meeting, San Francisco, April 6-10, #779, 2002.
146. M.-C. Bissery, P. Lejeune, P. Vrignaud. The Combination of Flavopiridol with Docetaxel (TAXOTERE®) is Synergistic in a Murine Adenocarcinoma Model MA13/C. ASCO, Orlando, May 18-21, #464, 2002
147. M.-C. Bissery, P. Vrignaud, P. Lejeune, E. Beys, Y. Archimbaud, M.F. Chiron, C. Combeau, K. Zinkewich-Peotti, D. Chaplin. Preclinical activity of AVE8062A, a tumor vasculature targeting agent. First International Conference on Tumor Vasculature, Cambridge, MA, June 12-14, 2002.
148. M.-C. Bissery, P. Lejeune, P. Vrignaud. In vivo synergy between platinum and AVE8062A, a tumor vasculature targeting agent. 94th AACR meeting, Washington, July 11-14, 2003.
149. P. Vrignaud, P. Lejeune, M.-C. Bissery. In vivo combination of flavopiridol with CPT-11 and docetaxel. 94th AACR meeting, Washington, July 11-14, #3719, 2003.
150. M.F. Chiron, F. Attenot, C. Lefranc, P. Vrignaud, P. Lejeune, M.-C. Bissery. Effects of the tumor vasculature targeting agent, AVE8062A, on endothelial cells *in vitro* and *in vivo*. 94th AACR meeting, Washington, July 11-14, 2003.
151. M. Chiron, P. Lejeune, P. Vrignaud, V. Polard-Housset, M.-C. Bissery. Evaluation pré-clinique d'agents anti-angiogènes et anti-vasculaires. Eurocancer, Paris, 8-10 juillet 2003.
152. M.-C. Bissery, P. Vrignaud, C. Combeau, J.-F. Riou, H. Bouchard, A. Commerçon, F. Lavelle. Preclinical evaluation of XRP9881A, a new taxoid. 95h AACR meeting, Orlando, # 5401, March 27-31, 2004.
153. P. Vrignaud, P. Lejeune, S. Nicolas, M.-C. Bissery. *In vivo* synergy between doxorubicin or vinorelbine and AVE8062A, a tumor vasculature targeting agent. 95h AACR meeting, Orlando, # 5433, March 27-31, 2004.
154. M. Guffroy, C. Dally, P. Vrignaud, E. Beys, M.-C. Bissery. Evaluation of tissue perfusion (tumor, spleen, heart) in mice after administration of AVE8062, a tumor vascular-targeting agent. 95h AACR meeting, Orlando, # 4699, March 27-31, 2004.
155. P. Vrignaud, P. Lejeune, S. Nicolas, M.-C. Bissery. *In vivo* synergy between cytotoxic agents and AVE8062A, a tumor vasculature targeting agent. 2 nd International Vascular Targeting Conference, Miami, May 16-18, 2004.